OncoMatch/Clinical Trials/NCT04989647
Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy
Is NCT04989647 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for cervical cancer.
The objective of the trial is to evaluate if adjuvant (chemo)radiation is associated with a disease-free survival benefit after radical surgery in patients with intermediate risk cervical cancer. The primary endpoint of the study is the disease-free survival from the day of randomisation. A total of 514 patients are required to achieve 80% power on 5% significance level with non-inferiority margin of 5% to test the difference between the ARMs using Cox proportional hazards model. The maximal tolerated margin for non-inferiority in 2-year DFS is 5% (including expected drop-out rate of 10%).
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage IIA (FIGO)
Excluded: Stage <IB1, >IIA
FIGO IB1-IIA
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: pelvic radiotherapy
Cannot have received: neoadjuvant chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04989647 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pelvic radiotherapy, neoadjuvant chemotherapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IIA is required.
Is there an age limit?
Yes. Patients must be 85 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages